RCM
DNA.WS

Rivernorth Capital Management’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Rivernorth Capital Management’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-79,998
Closed -$179K – 857
2021
Q4 		$179K Hold
79,998
– – 0.01% 468
2021
Q3 		$271K Buy
+79,998
New +$285K 0.01% 349

Other funds holding DNA.WS

CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

Rivernorth Capital Management's DNA.WS Position: Q1 2022 in Review

Rivernorth Capital Management sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q1 2022, closing a stake of 79,998 shares — an estimated $179K sold.

Rivernorth Capital Management first reported a position in DNA.WS in Q3 2021 and held it in 2 quarters. The position peaked at $271K in Q3 2021. 47 funds tracked by Wall St. Rank hold DNA.WS as of Q1 2022.

  • Rivernorth Capital Management reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q1 2022 after selling out during the quarter.
  • Rivernorth Capital Management sold 79,998 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q1 2022, an estimated $179K.
  • Rivernorth Capital Management first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q3 2021 and held it in 2 quarters.
  • Rivernorth Capital Management's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $271K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q1 2022.

Based on Rivernorth Capital Management's 13F filing for Q1 2022, filed 16 May 2022.